SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT03530319

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Studies on Macrolide-resistant Mycoplasma Pneumoniae in Taiwan- A Randomized Control Trial and MLVA Analysis

A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.

NCT03530319 Pneumonia, Mycoplasma
MeSH:Mycoplasma Infections Pneumonia, Mycoplasma Pneumonia Pleuropneumonia

2 Interventions

Name: Doxycycline

Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Type: Drug
Group Labels: 1


Name: Azithromycin

Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Type: Drug
Group Labels: 1


Primary Outcomes

Description: The timing (days) when fever subsides after treatment

Measure: Defervescence

Time: Up to 10 days

Secondary Outcomes

Description: The length of hospitalization

Measure: Hospital stay

Time: Up to 2 weeks

Purpose: Treatment

Allocation: Randomized

Parallel Assignment

There is one SNP


1 A2063G

In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---

HPO Nodes